Page 13 - Mark Mintun News Today

Alzheimer's progressively destroys thinking and memory, eventually robbing people of the ability to carry out the simplest of tasks.

WASHINGTON, May 4 — US pharmaceutical giant Eli Lilly yesterday announced its experimental Alzheimer’s drug significantly slowed cognitive and functional decline, results...

The company Eli Lilly has reported its drug - donanemab - slows the pace of Alzheimer's by about a third.

The experimental Alzheimer's drug developed by Eli Lilly slowed down progression of the disease in a clinical trial, the company said Wednesday. Eli Lilly plans to seek FDA approval for donanemab by the end of June after submitting data showing the drug reduces cognitive and functional declines.

US pharma giant Eli Lilly's experimental Alzheimer's drug slowed clinical decline by 35 per cent compared to placebo, and resulted in 40 per cent less decline on the ability to perform activities of daily living, said the company announcing ...

Experts say trial provides more evidence that targeting plaque proteins in brain can slow the disease’s progression.

More than half of patients with Alzheimer disease administered donanemab showed a significantly reduced cognitive and functional decline.

Remarkable Alzheimers drug reduces cognitive decline, study shows

The second such drug in a year raises hopes we can start treating dementia.

The success means patients and their caregivers could soon have another therapy shown to slow the disease alongside Leqembi — made by Cambridge biotech Biogen and Japanese drug maker Eisai — which was approved in January.